Company Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer.
The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration.
The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011.
Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Joel Lewis |
Contact Details
Address: 4960 Peachtree Industrial Boulevard, Suite 240 Norcross, Georgia 30071 United States | |
| Phone | 678 620 3186 |
| Website | galectintherapeutics.com |
Stock Details
| Ticker Symbol | GALT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133416 |
| CUSIP Number | 363225202 |
| ISIN Number | US3632252025 |
| Employer ID | 04-3562325 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joel Lewis CPA | President and Chief Executive Officer |
| Jack W. Callicutt CPA | Chief Financial Officer, Treasurer and Corporate Secretary |
| Dr. Khurram Jamil M.D. | Chief Medical Officer |
| Robert Tritt J.D. | General Counsel |
| Jim Wilkins Ph.D. | Head of CMC and Pharmaceutical Development |
| Beth Knowles | Executive Assistant and Officer Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |
| Apr 10, 2026 | EFFECT | Notice of Effectiveness |
| Apr 6, 2026 | UPLOAD | Filing |
| Mar 31, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |
| Jan 21, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |